Analysis Focusing on Plasma Von Willebrand Factor in Pachychoroid Neovasculopathy and Age-related Macular Degeneration

DOI: https://doi.org/10.21203/rs.3.rs-583008/v1

Abstract

Pachychoroid neovasculopathy (PNV) is a new disease concept. Some cases diagnosed as age-related macular degeneration (AMD) have been re-diagnosed as PNV. However, the biological features of PNV are still uncertain. The purpose of this study was to compare PNV and AMD by an analysis focusing on von Willebrand factor (VWF) and complement factor H (CFH). Ninety-seven patients who were previously diagnosed with treatment naïve AMD were enrolled in this study. They were re-classified PNV and AMD based on the clinical criteria and 33 patients were classified as PNV and 64 patients as AMD. We examined the clinical data and performed VWF multimer analysis and genetic polymorphisms in the CFH. PNV group was significantly younger than AMD group. The presence of unusually large VWF multimers (UL-VWFMs) and subretinal hemorrhage was significantly higher in PNV than in AMD. In the CFH I62V, allele A tended to be more frequent in PNV group and recessive homozygous (AA) was found only in PNV group. Thus, the genetic alternations in CFH may result in the residual UL-VWFMs and platelet thrombosis in the choriocapillaris of PNV. In conclusion, our results suggest the biological differences between PNV and AMD.

Introduction

Age-related macular degeneration (AMD) is a major retinal disease in the elderly,1 and choroidal neovascularization (CNV) has been considered a pathognomonic characteristic of AMD.

AMD is a multifactorial disease, and several causes have been suggested such as the sex of the individual, smoking, inflammation, and genetic factors.2,3 Complement factor H (CFH) is also a well-known risk factor for AMD,4,5 and it is activated by various pathways to initiate immune responses. This activation may then cause cell damage.6 CFH also promotes the degradation of the von Willebrand factor (VWF).79 VWF, a large glycoprotein with a multimeric mass structure, is exclusively produced by vascular endothelial cells as unusually large VWF multimers (UL-VWFMs) and is secreted into the plasma.10,11 The UL-VWFMs are cleaved by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). Although VWF plays an important role in pertinent coagulation, the presence of UL-VWFMs in the plasma is a risk factor for arterial thrombosis.12,13 Some researchers have reported an elevation of the plasma levels of VWF in treatment naïve AMD patients,14,15 and we also have demonstrated the higher percentages of existence of UL-VWFMs in patients with AMD compared to that in controls.16

Pang et al. have proposed a new disease concept called ‘pachychoroid neovasculopathy’ (PNV).1719 PNV is a disorder which is characterized by the development of choroidal neovascularization (CNV) secondary to central serous chorioretinopathy (CSC) or pachychoroid pigment epitheliopathy (PPE). However, the biological features of PNV are still uncertain.

We consider that many cases diagnosed as AMD may in fact be PNV and that the comparisons of the biological characteristics of AMD and PNV have not been well done.

Thus, the purpose of this study is to compare the characteristics of AMD to that of PNV. To accomplish this, we re-examined previously diagnosed AMD cases and separated them into PNV and AMD. We then performed VWF-based clinical and hematological analyses and genetic polymorphisms in the CFH to investigate the differences between two ocular disorders.

Results

The baseline characteristics of patients are available in Table 1. The median age was 77.0 years old and seventy were male (72%). There were 51 past or current smokers (53%). The median central choroidal thickness (CCT) was 217 µm and the median choroidal vessel diameter (CVD) was 144 µm. There was a strong positive correlation between CCT and CVD (r = 0.854, P < 0.001, Pearson's correlation coefficient). We also measured the blood type of all patients because it has been reported that VWF in individuals with blood type O is more likely to be cleaved by ADAMTS13.20,21

Table 1

The baseline characteristics of patients (n = 97)

Age, median (IQR)

77.0 (71.0–83.0)

Sex (male), n (%)

70 (72)

BMI, median (IQR), kg/m2

22.1 (19.9–23.6)

Smoking status, n (%)

 

Never

46 (47)

Past or current

51 (53)

Current

27 (28)

Brinkman Index, median (IQR)

150 (0-1000)

Blood type, n (%)

 

Type O

30 (31)

Type A

34 (35)

Type B

19 (17)

Type AB

14 (13)

CCT, median (IQR), µm

217 (140–291)

CVD, median (IOR), µm

144 (90–186)

PCV, n (%)

42 (43)

IQR, inter-quartile range

Brinkman Index, daily number of cigarettes multiplied by smoking years

CCT, central choroidal thickness

CVD, choroidal vessel diameter

PCV, polypoidal choroidal vasculopathy

 

Of the 97 total patients, 33 patients (34%) were diagnosed with PNV. The comparisons of patients based on PNV and AMD are summarized in Table 2. The patients in PNV group were significantly younger than those in AMD group (P = 0.001), and CCT was significantly thicker in PNV group (P < 0.001). CVD was also significantly greater in PNV than in AMD (P < 0.001). The rate of positive UL-VWFMs was significantly higher in PNV group than that in AMD group (36% vs 17%, P = 0.045), and the rate of subretinal hemorrhage was also significantly higher in PNV group than in AMD group (24% vs 6%, P = 0.02). There was no difference in the distribution of the blood type between the two groups.

Table 2

The comparison of patients; PNV and AMD

 

PNV

(n = 33)

AMD

(n = 64)

P value

Age, median (IQR)

72.0 (65.0–77.0)

78.5 (74.0–84.0)

0.001†

Sex (male), n (%)

24 (73)

46 (72)

1‡

BMI, median (IQR), kg/m2

22.1 (19.2–23.9)

22.1(20.0-23.1)

0.82†

Smoking status, n (%)

     

Never

15 (45)

31 (48)

-

Past or current

18 (55)

33 (52)

0.83‡

Current

8 (24)

19 (30)

0.64‡

Brinkman Index, median (IQR)

80 (0-920)

290 (0-1070)

0.71†

Blood type, n (%)

     

Type O

11 (33)

19 (30)

0.82‡

Type A

12 (36)

22 (34)

1‡

Type B

6 (18)

13 (20)

1‡

Type AB

4 (12)

10 (16)

0.77‡

CCT, median (IQR), µm

291 (260–349)

165 (120–214)

< 0.001†

CVD, median (IOR), µm

202 (186–236)

101 (81–143)

< 0.001†

UL-VWFM, n (%)

12 (36)

11 (17)

0.045‡

Subretinal hemorrhage, n (%)

8 (24)

4 (6)

0.020‡

PCV, n (%)

18 (55)

24 (38)

0.13‡

PNV, pachychoroid neovasculopathy

AMD, age related macular degeneration

IQR, inter-quartile range

CCT, central choroidal thickness

CVD, choroidal vessel diameter

PCV, polypoidal choroidal vasculopathy

†Mann-Whitney U test

‡ Fisher’s exact test

 

The significant differences were not found in the levels of plasma VWF Antigen (VWF: Ag), the activity of ADAMTS13 (ADAMTS13: AC), and the plasma vascular endothelial growth factor A (VEGF-A) between PNV group and AMD group (Fig. 1).

The comparisons of patients based on the presence of UL-VWFMs are summarized in Table 3. The rate of past or current smokers was significantly higher in UL-VWFM positive group than that in UL-VWFM negative group (P = 0.032). The frequency of PNV diagnosis was significantly higher in UL-VWFM positive group than that in UL-VWFM negative group (P = 0.045). The rate of subretinal hemorrhage (P < 0.001) and polypoidal choroidal vasculopathy (PCV) (P = 0.001) was also significantly higher in UL-VWFM positive group.

Table 3

The comparison of patients; UL-VWFM (+) and UL-VWFM (-)

 

UL-VWFM (+)

(n = 23)

UL-VWFM (-)

(n = 74)

P value

Age, median (IQR)

77.0 (70.5–86.0)

77.0 (71.0-81.8)

0.44†

Sex (male), n (%)

20 (87)

50 (68)

0.11‡

BMI, median (IQR), kg/m2

20.2 (18.7–23.7)

22.2 (20.4–23.3)

0.32†

Smoking status, n (%)

     

Never

6 (26)

39 (53)

-

Past or current

17 (74)

35 (47)

0.032‡

Current

6 (26)

22 (30)

0.80‡

Blood type, n (%)

     

Type O

8 (35)

22 (30)

0.80‡

Type A

8 (35)

26 (35)

0.80‡

Type B

4 (17)

15 (20)

1‡

Type AB

3 (13)

11 (15)

1‡

PNV, n (%)

12 (52)

21 (28)

0.045

AMD, n (%)

11 (48)

53 (72)

-

Subretinal hemorrhage, n (%)

8 (35)

4 (5)

< 0.001‡

PCV, n (%)

17 (74)

25 (34)

0.001‡

UL-VWFM, unusually large VWF multimer

IQR, inter-quartile range

PNV, pachychoroid neovasculopathy

AMD, age related macular degeneration

PCV, polypoidal choroidal vasculopathy

†Mann-Whitney U test

‡ Fisher’s exact test

 

ADAMTS13: AC was significantly lower in UL-VWFM positive group (P = 0.023). In contrast, there were no significant differences in VWF: Ag and VEGF-A between two groups (Fig. 2).

The distribution of gene polymorphisms in the CFH was showed in Table 4. In the I62V, although it was not significant, allele A tended to be more frequent in PNV group than in AMD group (OR, 1.41; 95%CI, 0.69–2.94), and recessive homozygous (AA) was found only in PNV group. On the other hand, in the Y402H, the recessive homozygous (CC) did not exist in both groups and there was no significant difference in allele C frequency.

Table 4 (A):

The CFH I62V and Y402H gene polymorphisms in PNV and AMD

  

I62V

Y402H

 

AA

GA

GG

CC

TC

TT

PNV

4

7

22

0

1

32

AMD

0

22

42

0

9

55

Table 4 (B):

odds ratio of each allele

  

I62V

Y402H

 

A

G

OR; A vs G (95% CI)

C

T

OR; C vs T (95% CI)

PNV

15

51

1.41 (0.69-2.94)

1

65

0.20 (0.03-1.28)

AMD

22

106

-

9

119

-

CFH, complement factor H

OR, odds ratio

CI, confidence interval

Discussion

Recently, Hosoda et al. used machine learning to review Japanese patients with AMD and suggested that 46% of cases were reclassified as PNV.22 However, the diagnosis criteria for PNV have not been clearly determined. Thus, we employed the definition criteria of previous reports18,23 and found a strong correlation between CCT and CVD. This suggests that the combination of both parameters in the diagnosis of PNV may lead to a more accurate assessment. In our study, 34% of cases were reclassified as PNV. This percentage was relatively lower than Hosoda’s report but still demonstrated that many cases previously diagnosed as AMD would be PNV by clinical characteristics.

Interestingly, our results showed the differences in biological characteristics between PNV and AMD. The rate in the presence of UL-VWFMs was significantly higher in PNV group than in AMD group. Furthermore in CFH I62V, although it was not significant, allele A tended to be more frequent in PNV group than in AMD group.

Recently, Yamashiro et al revealed that in CFH I62V, the G allele is a risk gene for developing AMD and a protective gene for developing PNV, while the A allele is a risk gene for developing PNV and a protective gene for developing AMD.19,24 Their report corresponds to our results but the comparisons of the biological characteristics of PNV and AMD had not been done.

We showed that subretinal hemorrhages were significantly higher in PNV group than in AMD group. Tagawa et al. reported that subretinal hemorrhages were found in 20% of patients with PNV.25 Nagai et al. also revealed that the pachyvessels (CVD ≥ 180 µm) and pachychoroid (CCT ≥ 220 µm) are risk factors for macular exudative changes after the induction phase of anti-VEGF injections.23 These findings suggested that the CNVs were more likely to hemorrhage in eyes in PNV group than in AMD group. Our results also showed that subretinal hemorrhages and PCV were significantly higher in the UL-VWFM positive group. The increased incidence of other thrombotic disorders with bleeding in UL-VWFM-positive patients has been shown in previous studies.10,12,13

A recent study reported that the density of the choriocapillaris was decreased in the PNV, and the decreased density areas were corresponding to the presence of pachyvessels.26 These results suggest that the pachyvessels may compress the choriocapillaris, then this leads to ischemia in the choroidal surface layer. Gelfand et al. have proposed a hemodynamic model of high shear stress acting on the choriocapillaris in eyes with AMD.27 Matsumoto et al. reported the presence of anastomosis and formation of collateral blood vessels in the pachyvessels, suggesting a long-term blood stasis.28 Thus, the vessels of the choriocapillaris in eyes with PNV would have especially higher shear stress than that in eyes with AMD.

It is known that the UL-VWFMs under low shear stress in large vessels take globular forms and are difficult to bind to platelets. However, in the micro vessels, UL-VWFMs are exposed to high shear stress and become extended forms that easily bind to platelets.10,29 Normally, ADAMTS13 has an antithrombotic function by promptly cleaving UL-VWFMs which maintains the proper hemostasis. We found that ADAMTS13: AC was significantly lower in UL-VWFM positive group than that in UL-VWFM negative group. That means remained UL-VWFMs existed although ADAMTS13 was consumed. Notably, the results of recent studies indicated that CFH promotes the cleavage of UL-VWFMs.79 That is, CFH specifically binds to the UL-VWFM A2 domain where located the cleavage site of ADAMTS13, then the UL-VWFM cleavage by ADAMTS13 is enhanced.7 Together with these results, genetic alterations of CFH in PNV may lead to the persistence of UL-VWFMs and may induce platelet thrombosis. In the CFH I62V polymorphisms, our results showed that allele A tended to be more frequent in PNV group than in AMD group and recessive homozygous (AA) was found only in PNV group. This may suggest a difference in the pathogenesis between PNV and AMD.

The choriocapillaris in patients with PNV is supposed to be under high shear stress suppressed by the pachyvessels. This situation may further activate UL-VWFM leading to thrombus formation and the further deterioration of blood flow in the choriocapillaris. The deterioration of blood flow may promote CNV formation and make it more likely to bleeding, subretinal hemorrhage.

There are several limitations in this study. First, we used a relatively small sample size for the comparisons. Second, the long-term clinical course is still unknown because we evaluated only at the first examination. Further long-term follow-up is desired to determine the clinical differences of the two groups.

Conclusions

The genetic alternations in CFH may result in the residual UL-VWFMs in the plasma and the formation of platelet thrombosis in the choriocapillaris. Our findings suggest biological differences between PNV and AMD.

Methods

This was a cross-sectional study of 97 treatment naïve patients who had been diagnosed with exudative AMD based on the definition of the Japanese AMD Study Group.30 In more detail, exudative AMD was diagnosed in patients who were over 50 years old with at least one following abnormalities (CNV, serous pigment epithelium detachment, subretinal hemorrhage, and fibrous scars) within an area of 6000 µm in diameter centered at the fovea. High myopia (over − 6.0 diopter), uveitis, trauma, and other degenerative diseases were excluded. All participants were patients of the Nara Medical University Hospital, Kashihara City, Nara Prefecture, Japan from 2014 to 2019. This study protocol was approved by the Institutional Review Board of the Nara Medical University and a signed informed consent was obtained from all the participants before the examinations. This study was performed in accordance with the Declaration of Helsinki. We confirm that all methods were performed in accordance with the relevant guidelines and regulations.

All patients underwent conventional ophthalmological examinations including slit-lamp examinations, fundus examinations, OCT (Spectralis, Heidelberg Engineering, Dossenheim, Germany), fundus photography, fluorescein angiography (FA), and indocyanine green angiography (ICGA) at the initial examination. The fundus photographs and OCT images were used to determine the presence of subretinal hemorrhages. After re-examination of all of the images, the patients were diagnosed with PNV or AMD.

According to the recent reports on PNV analysis,18,19,22,23,25,31 we diagnosed a patient as PNV when all following criteria were satisfied: Type1 CNV (including PCV), CVD ≥ 180 µm, CCT ≥ 220 µm, absence of drusen in the fundus photographs, and increased choroidal vascular permeability in the late phase of the ICGA images (Fig. 3). PCV was characterized by polypoidal lesions in ICGA. CVD was defined as the vertical diameter of the largest vessel in the Haller's layer. CVD and CCT were measured independently by two different researchers using a scale bar contained within the OCT system.23 The judgments were made independently by two retinal specialists, and in cases when the judgments were different, the final decision was made by a macular disease specialist (N.O.).

We collected blood samples by venipuncture at the initial examination. The whole blood samples were stored in tubes containing a 1:9 volume of 3.8% trisodium citrate. The plasma was separated and saved at -80º C. For the measurements, the plasma was thawed and maintained at 37º C before the measurements. The level of plasma VWF Antigen (VWF: Ag) was measured by sandwich enzyme-linked immunosorbent assay (ELISA) using a rabbit anti–human VWF polyclonal antiserum (DAKO, Glostrup, Denmark).13 We determined the activity of ADAMTS13 (ADAMTS13: AC) by a chromogenic ADAMTS13 activity ELISA kit (Kainos, Tokyo, Japan).32 The 100% reference value was defined as the amount of VWF: Ag and ADAMTS13: AC in the plasma of 20 normal volunteers (10 men and 10 women ages 20 to 40 years). We also measured the plasma vascular endothelial growth factor A (VEGF-A) by ELISA (Quantikine VEGF ELISA kit; R&D Systems, Minneapolis, Minnesota, USA). The VWF multimers were analyzed by the method of Ruggeri and Zimmerman33, modified by Warren et al.34 The measurements were made under the conditions described by Budde et al,35 and we defined the high molecular weight bands that were not detected in normal plasma as UL-VWFMs. Then, we performed densitometric analysis using ImageJ (National Institute of Health, Bethesda, Maryland, USA). UL-VWFMs were defined as being positive when the ratio of UL-VWFMs to total VWF was > 1% (Fig. 4).36

We extracted genomic DNA from the leukocytes by a genomic DNA kit (QIAmpDNA; Qiagen, Valencia, California, USA) and genotyped the SNPs of p.I62V (rs800292) and p.Y402H (rs1061170) in CFH. Polymerase chain reaction (PCR) with specific primers was used to amplify the polymorphic sites.37 The PCR products were used as the templates for direct DNA sequencing (Applied Biosystems, Foster City, California, USA) on an automated sequencer (3730xl DNA analyzer; Applied Biosystems). The genotypes in the CFH were classified based on the previous studies.38,39

Statistical analyses

Two-tailed Mann-Whitney U tests were used to compare the averages of continuous variables (such as age) and Fisher’s exact tests to compare the proportions of categorical variables (such as sex) between groups. Odds ratios and 95% confidence intervals were calculated by using Fisher’s exact tests. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria).40 Since both CCT and CVD followed a normal distribution, the correlation was evaluated at Pearson's correlation coefficient. On the other hand, the measured values of VEGF-A were not normally distributed, and the exact values were not partially shown because the values were below the minimum detectable dose of 9 pg/ml. Therefore, a non-parametric test was applied, and a conservative value of 8 pg/ml was input for each value below the MDD when performing the calculations. The threshold for statistically significance was P < 0.05.

Declarations

Acknowledgements

The authors thank Hiroki Tsujinaka for useful discussions, Yutaro Mizusawa and Hironobu Jimura for the data collection.

Author contributions

Conception and design: M.M., T.U., and N.O., Writing the article: H.H, M.Y., M.M., N.O., Analysis: H.H, M.Y., M.H., K.S.

Data availability

The datasets generated or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare no competing interests.

References

  1. Ricci, F. et al. Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. Int J Mol Sci 21, doi:10.3390/ijms21218242 (2020).
  2. Heesterbeek, T. J., Lorés-Motta, L., Hoyng, C. B., Lechanteur, Y. T. E. & den Hollander, A. I. Risk factors for progression of age-related macular degeneration. Ophthalmic Physiol Opt 40, 140-170, doi:10.1111/opo.12675 (2020).
  3. Smith, W. et al. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology 108, 697-704, doi:10.1016/s0161-6420(00)00580-7 (2001).
  4. Klein, R. J. et al. Complement factor H polymorphism in age-related macular degeneration. Science 308, 385-389, doi:10.1126/science.1109557 (2005).
  5. Toomey, C. B., Johnson, L. V. & Bowes Rickman, C. Complement factor H in AMD: Bridging genetic associations and pathobiology. Prog Retin Eye Res 62, 38-57, doi:10.1016/j.preteyeres.2017.09.001 (2018).
  6. Morgan, B. P. & Harris, C. L. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov 14, 857-877, doi:10.1038/nrd4657 (2015).
  7. Feng, S. et al. The interaction between factor H and Von Willebrand factor. PLoS One 8, e73715, doi:10.1371/journal.pone.0073715 (2013).
  8. Nolasco, L., Nolasco, J., Feng, S., Afshar-Kharghan, V. & Moake, J. Human complement factor H is a reductase for large soluble von Willebrand factor multimers--brief report. Arterioscler Thromb Vasc Biol 33, 2524-2528, doi:10.1161 / ATVBAHA.113.302280 (2013).
  9. Rayes, J. et al. The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood 123, 121-125, doi:10.1182/blood-2013-04-495853 (2014).
  10. Crawley, J. T., de Groot, R., Xiang, Y., Luken, B. M. & Lane, D. A. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood 118, 3212-3221, doi:10.1182/blood-2011-02-306597 (2011).
  11. Matsushita, K. et al. Vascular endothelial growth factor regulation of Weibel-Palade-body exocytosis. Blood 105, 207-214, doi:10.1182/blood-2004-04-1519 (2005).
  12. Buchtele, N., Schwameis, M., Gilbert, J. C., Schörgenhofer, C. & Jilma, B. Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence. Thromb Haemost 118, 959-978, doi:10.1055/s-0038-1648251 (2018).
  13. Matsumoto, M. et al. Platelets treated with ticlopidine are less reactive to unusually large von Willebrand factor multimers than are those treated with aspirin under high shear stress. Pathophysiol Haemost Thromb 34, 35-40, doi:10.1159/000088546 (2005).
  14. Lip, P. L., Blann, A. D., Hope-Ross, M., Gibson, J. M. & Lip, G. Y. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. Ophthalmology 108, 705-710, doi:10.1016/s0161-6420(00)00663-1 (2001).
  15. Malukiewicz-Wiśniewska, G., Rość, D., Kałuzny, B. & Kałuzny, J. J. [Von Willebrand factor in plasma of patients with age related macular degeneration]. Klin Oczna 107, 70-72 (2005).
  16. Yamashita, M. et al. Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration. Sci Rep 8, 1491, doi:10.1038/s41598-018-19473-0 (2018).
  17. Pang, C. E. & Freund, K. B. Pachychoroid neovasculopathy. Retina 35, 1-9, doi:10.1097/IAE.0000000000000331 (2015).
  18. Miyake, M. et al. Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep 5, 16204, doi:10.1038/srep16204 (2015).
  19. Yamashiro, K., Hosoda, Y., Miyake, M., Ooto, S. & Tsujikawa, A. Characteristics of Pachychoroid Diseases and Age-Related Macular Degeneration: Multimodal Imaging and Genetic Backgrounds. J Clin Med 9, doi:10.3390/jcm9072034 (2020).
  20. Bowen, D. J. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 1, 33-40, doi:10.1046/j.1538-7836.2003.00007.x (2003).
  21. Gallinaro, L. et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 111, 3540-3545, doi:10.1182/blood-2007-11-122945 (2008).
  22. Hosoda, Y. et al. Deep phenotype unsupervised machine learning revealed the significance of pachychoroid features in etiology and visual prognosis of age-related macular degeneration. Sci Rep 10, 18423, doi:10.1038/s41598-020-75451-5 (2020).
  23. Nagai, N. et al. Dynamic changes in choroidal conditions during anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy. Sci Rep 9, 11389, doi:10.1038/s41598-019-47738-9 (2019).
  24. Hosoda, Y. et al. CFH and VIPR2 as susceptibility loci in choroidal thickness and pachychoroid disease central serous chorioretinopathy. Proc Natl Acad Sci U S A 115, 6261-6266, doi:10.1073/pnas.1802212115 (2018).
  25. Tagawa, M. et al. Characteristics of pachychoroid neovasculopathy. Sci Rep 10, 16248, doi:10.1038/s41598-020-73303-w (2020).
  26. Baek, J., Kook, L. & Lee, W. K. Choriocapillaris Flow Impairments in Association with Pachyvessel in Early Stages of Pachychoroid. Sci Rep 9, 5565, doi:10.1038/s41598-019-42052-w (2019).
  27. Gelfand, B. D. & Ambati, J. A Revised Hemodynamic Theory of Age-Related Macular Degeneration. Trends Mol Med 22, 656-670, doi:10.1016/j.molmed.2016.06.009 (2016).
  28. Matsumoto, H., Kishi, S., Mukai, R. & Akiyama, H. Remodeling of macular vortex veins in pachychoroid neovasculopathy. Sci Rep 9, 14689, doi:10.1038/s41598-019-51268-9 (2019).
  29. Kroll, M. H., Hellums, J. D., McIntire, L. V., Schafer, A. I. & Moake, J. L. Platelets and shear stress. Blood 88, 1525-1541 (1996).
  30. Takahashi, K., Ishibashi, T., Ogur, Y., Yuzawa, M. [Classification and diagnostic criteria of age-related macular degeneration]. Nippon Ganka Gakkai Zasshi 112, 1076-1084 (2008).
  31. Biçer, Ö., Demirel, S., Yavuz, Z., Batioğlu, F. & Özmert, E. Comparison of Morphological Features of Type 1 CNV in AMD and Pachychoroid Neovasculopathy: An OCTA Study. Ophthalmic Surg Lasers Imaging Retina 51, 640-647, doi:10.3928/23258160-20201104-06 (2020).
  32. Kato, S. et al. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 46, 1444-1452, doi:10.1111/j.1537-2995.2006.00914.x (2006).
  33. Ruggeri, Z. M. & Zimmerman, T. S. Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest 65, 1318-1325, doi:10.1172/jci109795 (1980).
  34. Warren, C. M., Krzesinski, P. R. & Greaser, M. L. Vertical agarose gel electrophoresis and electroblotting of high-molecular-weight proteins. Electrophoresis 24, 1695-1702, doi:10.1002/elps.200305392 (2003).
  35. Budde, U. et al. Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes. Thromb Haemost 63, 312-315 (1990).
  36. Yoshikawa, T. et al. Ischaemia-reperfusion injury with Pringle's maneuver induces unusually large von Willebrand factor multimers after hepatectomy. Thromb Res 183, 20-27, doi:10.1016/j.thromres.2019.09.005 (2019).
  37. Ohkuma, Y. et al. Retinal angiomatous proliferation associated with risk alleles of ARMS2/HTRA1 gene polymorphisms in Japanese patients. Clin Ophthalmol 8, 143-148, doi:10.2147/OPTH.S56483 (2014).
  38. Wang, Z. Y. et al. Systematic review and meta-analysis of the association between complement factor H I62V polymorphism and risk of polypoidal choroidal vasculopathy in Asian populations. PLoS One 9, e88324, doi:10.1371/journal.pone.0088324 (2014).
  39. Chen, G. et al. Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis. Sci Rep 5, 14517, doi:10.1038/srep14517 (2015).
  40. Kanda, Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48, 452-458, doi:10.1038/bmt.2012.244 (2013).